XIN.STU XINHUA PHARMA -H- (XIN.SG)
- Market cap
- -
- P/E
- 14.5x
- P/B
- 0.56x
- ROE
- 4.9%
- Dividend yield
- 2.98%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is XIN.STU undervalued?
Graham numberThe Graham number of XINHUA PHARMA -H- (XIN.SG) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
XINHUA PHARMA -H- (XIN.SG) fundamental analysis
No fundamental analysis for XINHUA PHARMA -H- (XIN.SG) yet.
XINHUA PHARMA -H- (XIN.SG) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About XINHUA PHARMA -H- (XIN.SG)
There is no Profile data available for XIN.SG.
Full company profileXINHUA PHARMA -H- (XIN.SG) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
XINHUA PHARMA -H- (XIN.SG) annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.01B | 4.52B | 5.21B | 5.61B | 6.01B | 6.56B | 7.50B | 8.10B | 8.47B | 8.75B | 8.08B |
| Gross Profit | 1.00B | 1.27B | 1.56B | 1.87B | 1.81B | 1.77B | 2.04B | 2.39B | 2.04B | 1.64B | 1.51B |
| Operating Income | 152M | 276M | 365M | 458M | 543M | 499M | 543M | 612M | 596M | 442M | 410M |
| EBITDA | - | 604M | 682M | 781M | 857M | 909M | 1.01B | 1.09B | 1.11B | 989M | 318M |
| Net Income | 122M | 210M | 251M | 300M | 325M | 349M | 411M | 497M | 470M | 290M | 260M |
| EPS | - | 0.34 | 0.40 | 0.48 | 0.52 | 0.56 | 0.61 | 0.74 | 0.69 | 0.42 | 0.37 |
| Balance Sheet | |||||||||||
| Total Assets | 4.72B | 5.27B | 5.92B | 6.44B | 7.09B | 7.33B | 8.26B | 8.29B | 9.02B | 9.19B | 8.81B |
| Total Liabilities | 2.64B | 2.69B | 3.12B | 3.33B | 3.70B | 3.68B | 3.92B | 3.51B | 3.80B | 3.73B | 3.22B |
| Shareholders' Equity | 1.99B | 2.48B | 2.69B | 2.97B | 3.22B | 3.47B | 4.13B | 4.55B | 4.99B | 5.21B | 5.34B |
| Cash & Short-term Investments | 561M | 731M | 778M | 690M | 856M | 745M | 1.16B | 918M | 1.25B | 1.40B | 1.19B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 439M | 390M | 345M | 348M | 420M | 259M | 758M | 265M | 368M | 534M | - |
| Capital Expenditure | 227M | 261M | 386M | 367M | 280M | 249M | 245M | 325M | 212M | 116M | 94.5M |
| Free Cash Flow | - | 129M | -41.4M | -18.2M | 140M | 9.89M | 513M | -59.9M | 155M | 418M | 148M |
| Ratios | |||||||||||
| ROE | 6.1% | 8.5% | 9.3% | 10.1% | 10.1% | 10.1% | 10.0% | 10.9% | 9.4% | 5.6% | 4.9% |
| ROA | 2.6% | 4.0% | 4.2% | 4.7% | 4.6% | 4.8% | 5.0% | 6.0% | 5.2% | 3.2% | 3.0% |
| Net Profit Margin | 3.0% | 4.6% | 4.8% | 5.4% | 5.4% | 5.3% | 5.5% | 6.1% | 5.6% | 3.3% | 3.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
XINHUA PHARMA -H- (XIN.SG) dividends
- Dividend yield
- 2.98%
- Forward dividend
- -
- Payout ratio
- 72.4%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 210M | 0.30 | 72.4% |
| 2024 | CNY 226M | 0.33 | 48.1% |
| 2023 | CNY 176M | 0.26 | 35.4% |
| 2022 | CNY 163M | 0.24 | 39.7% |
| 2021 | CNY 148M | 0.24 | 42.6% |
| 2020 | CNY 127M | 0.20 | 39.0% |
| 2019 | CNY 116M | 0.19 | 38.8% |
| 2018 | CNY 89.8M | 0.14 | 35.8% |
| 2017 | CNY 54.4M | 0.09 | 26.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns XINHUA PHARMA -H- (XIN.SG)
Ownership data of XINHUA PHARMA -H- (XIN.SG) is not available yet.
XINHUA PHARMA -H- (XIN.SG) company profile
- Company name
- XINHUA PHARMA -H- (XIN.SG)
- Ticker
- XIN.STU
- ISIN
- CNE100000411
- Exchange
- Stuttgart Exchange
- Sector
- Other
- Industry
- Metals & Mining
- Fiscal year end
- December
- Address
- Website
- -
About XINHUA PHARMA -H- (XIN.SG)
There is no Profile data available for XIN.SG.